Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study

American Journal of Medicine

Volumn 101, Issue 6, 1996, Pages 627-634

  Mercuri, Michele ^a   Bond, M Gene ^a   Sirtori, Cesare R ^b   Veglia, Fabrizio ^c   Crepaldi, Gaetano ^d   Feruglio, F Saverio ^e   Descovich, Giancarlo ^f   Ricci, Giorgio ^g   Rubba, Paolo ^h   Mancini, Mario ^a,h   Gallus, Giuseppe ^b,c   Bianchi, Giuseppe ⁱ   D'Alò, Gioacchino ⁱ   Ventura, Alessandro ^j  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c HS Raffaele ^*  (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; B SCAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; CAROTID STENOSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; ITALY; LIPIDS; MALE; MIDDLE AGED; PRAVASTATIN; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA;

EID: 8244249463     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00333-6     Document Type: Article

References (31)

1. 1. Holme I, Enger SC, Helgeland A, et al. Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries. Arteriosclerosis. 1981:1:250-256.
2. 2. Hertzer NR, Young JR, Seven EG, et al. Coronary angiography in 506 patients with extracranial cerebrovascular disease. Arch Intern Med. 1985:145:849-852.
3. 3. Rubens J, Espeland MA, Ryu J, et al. Individual susceptibility to extracranial carotid atherosclerosis. Arteriosclerosis. 1988:8:389-397.
4. 4. Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the association between carotid artery atherosclerosis and coronary artery atherosclerosis. Stroke. 1990:82:1230-1242.
5. 5. Herrington DM, Bean J, Mercuri M. Strong correlation between carotid artery wall thickness and quantitative coronary artery angiography assessment of coronary atherosclerosis. Circulation. 1994;90:1-535. Abstract.
6. 6. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulartion. 1986:74:1399-1406.
7. 7. Mercuri M. Noninvasive imaging protocols to detect and monitor carotid atherosclerosis progression. Am J Hypertens. 1994;7:23S-29S.
8. 8. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol. 1989:129:687-702.
9. 9. O'Leary DH, Polack JF, Wolfson SK, et al. On behalf of the CHS Collaborative Research Group. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. Stroke. 1991:22:1155-1163.
10. 10. Salonen JT, Seppanen K, Rauramaa R, Salonen R. Risk factors for carotid atherosclerosis: the Kuopio lschaemic Heart Disease Risk Factors Study. Ann Med. 1989:21:227-229.
11. 11. Bots ML, Breslau PJ, Briet E, et al. Cardiovascular determinants of carotid artery disease. The Rotterdam Study. Hypertension. 1992;19:717-720.
12. 12. Ultrasound in Clinical Trials of Atherosclerosis Minisymposium. Introduction. J Intern Med. 1994:236:551-586.
13. 13. Sirtori CR, Bianchi G, Bond MG, et al. Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study. Int J Cardiac Imag. 1995;11(suppl 2):119-124.
14. 14. lnsull W Jr, Bond MG, Wilmoth S, et al. Ultrasound lesions of the carotid artery and risk factors in men. In: S Glagov, Newman WP III, Schaffer SA, eds. Pathobiology of the Human Atherosclerotic Plaque. New York: Springer; 1990:663-669.
15. 15. European Atherosclerosis Society Study Group. The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Euro Heart J. 1988:9:571-600.
16. 16. Bond MG, Mercuri M. What are the most sensitive ultrasound endpoints? VII European Meeting on Hypertension. Lessons from the MIDAS Trial, Abstract Book; 1995:4-5.
17. 17. Mercuri M, Bond MG, Nichols FT, et al. Baseline reproducibility of B-mode ultrasound imaging measurements of carotid intima media thickness: the Multicenter lsradipine Diuretic Atherosclerosis Study (MIDAS). J Cardiovas Diag Proced. 1993:11:241-255.
18. 18. Riley WA, Barnes RW, Applegate WB, et al. Reproducibility of noninvasive ultrasonic measurements of carotid atherosclerosis. The Asymptomatic Carotid Artery Plaque Study (ACAPS). Stroke. 1992;23:1062-1068.
19. 19. Byington RP, Evans GW, Applegate WB, Furberg CD. Predictors of carotid atherosclerosis progression. Circulation. 1994;90(4-2):1-127. Abstract.
20. 20. Espeland MA, Applegate WB, Furberg CD, et al, for the ACAPS Investigators. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries in postmenopausal women. Am J Epidemiol. 1995;142:1011-1019.
21. 21. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLACID. Am J Cardiol. 1995:75:455-459.
22. 22. Furberg CD, Adams HP Jr, Applegate WB, et al, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1676-1687.
23. 23. Hodis HN, Mack WJ, Labree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy, a randomized, controlled clinical trial. Ann Intern Med. 1996;124:584-556.
24. 24. Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). a population-based primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid anc femoral arteries. Circulation. 1995;92(7):1758-1764.
25. 25. Scandinavian Simvastatin Survival Study Group. Ramdomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994:344:1383-1389.
26. 26. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 1995:333:1301-1307.
27. 27. The West of Scotland Coronary Prevention Study Group. Computerized record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study J Clin Epidemiol. 1995:48:1441-1452.
28. 28. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
29. 29. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992:339:563-569.
30. 30. Blankenhorn DH, Azen SP, Kramsh DM, et al, and the MARS Research Group: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993:119:969-976.
31. 31. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995;92:2419-2425.